Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Net Income | 83.86% | -- | -296.64% | ||
| Total Depreciation and Amortization | -100.00% | -- | -76.09% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -95.68% | -- | 2,669.92% | ||
| Change in Net Operating Assets | -102.64% | -- | 907.87% | ||
| Cash from Operations | 20.07% | -- | 28.18% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | 255.87% | -- | -- | ||
| Total Debt Repaid | -611.11% | -- | 82.69% | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -15.82% | -- | 1,813.46% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 650.00% | -- | 99.54% | ||